oral.semaglutide Oral Semaglutide for Weight Loss Oral Semaglutide Gets FDA Approval
Description
Medical app, 4.8/5, 1M+ downloads
Triple receptor agonism studies (GLP-1, GIP, glucagon)
Weight loss on tirzepatide varies significantly between individuals due to metabolic, lifestyle, and genetic factors
A mechanism match
June 6, 2025 A large retrospective review of more than 100,000 patients found the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in moderate peripheral artery disease (PAD) is associated with a decreased rate of cardiovascular events, major limb events and inpatient admissions
Research & Development purposes only
